Why Kura Oncology, Inc.’s (KURA) Stock Is Up 8.44%
As of Tuesday, October 20, Kura Oncology, Inc.’s KURA share price has surged by 8.44%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Commentary & Analysis
Why Kura Oncology, Inc.’s (KURA) Stock Is Down 6.27%
As of Wednesday, September 23, Kura Oncology, Inc.’s KURA share price has dipped by 6.27%, which has investors questioning if this is right time to buy.Michael Rose
Why Kura Oncology, Inc.’s (KURA) Stock Is Up 5.22%
As of Thursday, September 17, Kura Oncology, Inc.’s KURA share price has surged by 5.22%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Kura Oncology, Inc.’s (KURA) Stock Is Up 8.74%
As of Tuesday, August 25, Kura Oncology, Inc.’s KURA share price has surged by 8.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Kura Oncology, Inc.’s (KURA) Stock Is Up 10.08%
As of Tuesday, August 25, Kura Oncology, Inc.’s KURA share price has surged by 10.08%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | KURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $832.7 | $217.7 | 44% |
|
| Shares Out (Mil) | 88.9 | 53.7 | 60% |
|
| Institutional Ownership | 98.1% | 92.9% | 77% |
|
| Float (Mil) | 70.5 | 41.4 | 54% |
|
| Beta | 0.38 | 0.95 | 22% |
|
| Avg Daily Volume (000s) | 1,689 | 583 | 79% |
|
| Price Change (52-week) |
(7.6%) | 45.5% | 46% |
|
| Growth | KURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (25.5%) | (10.1%) | 16% |
|
| EPS (5yr) | (13.5%) | 15.7% | 19 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.6%) | (15.7%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.806) | ($3.173) | ($2.349) | |
| Month Ago EPS | ($0.807) | ($3.164) | ($2.297) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | ($0.892) | ($3.442) | ($2.580) | |
| Year/Year Chg | 4.8% | (0.2%) | (38.0%) | |
| Financials | KURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $77 | $37 | 24% |
|
| Net Income (TTM) (Mil) | ($297) | ($44) | 5% |
|
| EPS (TTM) | ($3.361) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($112) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($12) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $403 | $175 | 32% |
|
| Valuation | KURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.33 | 2.11 | 95% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | KURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (236.7%) | 66.5% | 1% |
|
| Net Margin | (384.3%) | (74.8%) | 3% |
|
| ROA | (46.7%) | (47.1%) | 12% |
|
| ROE | (167.7%) | (54.1%) | 5% |
|
| Liabilities to Assets | 91.8% | 29.0% | 89% |
|
| F-Score | 2 | 2 | 7% |
|
Kura Oncology, Inc. did not pass any screens on 10/19/2026.
